Ro Shauna Rothwell
National Institutes of Health(US)National Institute of Allergy and Infectious Diseases(US)
Publications by Year
Research Areas
HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Retinal Diseases and Treatments, HIV/AIDS drug development and treatment, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials(2017)300 cited
- → Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial(2022)157 cited
- → Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study(2019)125 cited
- → Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial(2019)105 cited
- → An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults(2023)92 cited
- → Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial(2022)86 cited
- → Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial(2021)63 cited
- → Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial(2022)40 cited
- → Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS(2024)6 cited
- → Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection(2025)6 cited